35 results about "Filamin" patented technology

Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and / or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

A method of inhibiting phosphorylation of the tau protein and / or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

The invention relates to a method for expressing Reteplase (rPA) in Escherichia coli by using a dual plasmid system. The method comprises the following steps of: performing polymerase chain reaction (PCR) amplification to obtain gene segment of the rPA, and cloning the gene segment into a vector pET22b to construct a recombinant plasmid pET22b-rPA; co-transforming the pET22b-rPA and pET40b into Escherichia coli BL21 (DE3) by using different resistances of the pET22b-rPA and the pET40b, and screening engineering bacteria under ampicillin (Amp) and kanamycin (Kan) double resistance selection pressure; and performing inducible expression on the engineering bacteria by using isopropyl-beta-D-1-thiogalactopyranoside (IPTG) to obtain the soluble rPA target protein. Through detection by a fibrin plate method, the rPA protein obtained in the method is not needed to be subjected to renaturation and has obvious thrombolytic activity.

Immunohistochemical methods and compositions for the typing of molecular subgroups of medulloblastomas are provided. The methods comprise determining a protein expression profile for a sample obtained from a medulloblastoma by detecting expression of GAB 1, filamin A, or at least two biomarker proteins selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and typing the medulloblastoma as a WNT pathway tumor, a SHH pathway tumor, or a non-WNT / non-SHH tumor based on this protein expression profile. Kits for typing a medulloblastoma according to these three molecular subgroups are provided. The kits comprise at least two antibodies, wherein each of said antibodies specifically binds to a distinct biomarker protein selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and can optionally comprise one or more of instructions for use, reagents for detecting antibody binding to one or more of said biomarker proteins, and one or more positive control samples.

The present invention relates to a pharmaceutical composition for preventing or treating a hypertrophic scar. The present inventors acknowledged that expression inhibition of thioredoxin 5, PRRC1, S100A11, galectin 1, filamin A, eukaryotic initiation factor-5A, annexin A2 and fatty acid binding proteins 5 can be a new target for relieving and treating a hypertrophic scar. According to the present invention, the treatability of a hypertrophic scar is confirmed by producing thioredoxin 5-, PRRC1-, S100A11-, galectin 1-, filamin A-, eukaryotic initiation factor-5A-, annexin A2- and FABP5-specific siRNAs. Therefore, the knockdown of the proteins or genes coding same induces cell death in a hypertrophic scar and reduces collagen expression and thus can be highly useful for scar treatment.

The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.

The invention provides method for diagnosis, monitoring, and prognosis of prostate cancer using one or more of keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9, and PSA. The invention provides kits for practicing the methods of the invention.

A composition and method are disclosed that utilize an isolated polypeptide or analog thereof to inhibit the interaction of a mu-opioid receptor with filamin A. A contemplated polypeptide has an amino acid residue sequence illustrated by the formula: W—[X1X2X3 . . . X43X44X45]nValAlaX48GlyLeu[X51X52X53 . . . X94X95X96]m—Y wherein the various elements are defined elsewhere. A contemplated method can be used to select a VAKGL-binding compound.

Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and / or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

The invention provides for a method of preparing an isolated serum fraction of platelet rich fibrin (PRF), comprising the steps ofa. providing platelet rich plasma (PRP) without the addition of an anticoagulant;b. clotting the PRP to obtain a coagel of PRF; andc. separating the coagel to isolate the serum fraction which comprises an activated platelet releasate;and further provides for the isolated serum fraction obtained by such method, and its medical use.

Compounds represented by formula (I) belowand pharmacologically acceptable salts thereof and solvates of them; pharmaceutical compositions and dynamin-related protein 1 (Drp1)-filamin complex formation inhibitors containing them; and uses of the compounds, salts, solvates, pharmaceutical compositions, and (Drp1)-filamin complex formation inhibitors for use as a prophylactic or therapeutic agent.

The present invention provides compositions and methods for the diagnosis and treatment of Kawasaki disease. More specifically, the proteome of KD patients is enriched in meprin A, filamin B, and filamin C, which serve as biomarkers (and potential therapeutic targets) for KD. Accordingly, detection of these biomarkers using the compositions and methods provided herein can inform the delivery of therapy to a subject.

In joint reconstruction, repair and cushioning applications, a synthetic polypeptide material is useful that contains cross-linked polypeptides that are modeled on human elastin or other fibrous proteins. The polypeptides comprise at least three consecutive beta-sheet / beta-turn structures and at least one amino acid residue that participates in cross-linking.

The disclosure teaches antibodies that are useful, inter alia, in methods for detecting and treating human cancer. In a particular aspect, the disclosure teaches novel antibodies that are useful for detecting and treating human breast cancer. In some embodiments, the disclosure teaches novel antibodies that bind to filamin A. In some embodiments, the antibodies are intrabodies.

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

Immunohistochemical methods and compositions for the typing of molecular subgroups of medulloblastomas are provided. The methods comprise determining a protein expression profile for a sample obtained from a medulloblastoma by detecting expression of GAB1, filamin A, or at least two biomarker proteins selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and typing the medulloblastoma as a WNT pathway tumor, a SHH pathway tumor, or a non-WNT / non-SHH tumor based on this protein expression profile. Kits for typing a medulloblastoma according to these three molecular subgroups are provided. The kits comprise at least two antibodies, wherein each of said antibodies specifically binds to a distinct biomarker protein selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and can optionally comprise one or more of instructions for use, reagents for detecting antibody binding to one or more of said biomarker proteins, and one or more positive control samples.